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Abstract
HFE-hemochromatosis is a disease characterized by a systemic iron overload 
phenotype mainly associated with mutations in the HFE protein (HFE) gene. 
Osteoarthritis (OA) has been reported as one of the most prevalent complications in HFE-
hemochromatosis patients but the mechanisms associated with its onset and progression 
remain incompletely understood. In this study, we have characterized the response to high 
iron concentrations of a primary culture of articular chondrocytes isolated from newborn 
Hfe-KO mice and compared the results to a similar experiment developed in cells from 
C57BL/6 (WT) mice. Our data provide evidences that both WT and Hfe-KO derived 
chondrocytes, when exposed to 50 µM of iron, develop characteristics of an OA-related 
phenotype, such as an increased expression of metalloproteases, a decreased extracellular 
matrix production and a lower level of expression of aggrecan. In addition, Hfe-KO cells 
also showed an increased expression of Mmp3, indicating an increased susceptibility to 
intracellular iron accumulation. Accordingly, upon treatment with 50 µM of iron, these 
chondrocytes were found to preferentially differentiate towards hypertrophy with 
increased expression of collagen I, transferrin and downregulation of SRY (Sex-
Determining Region Y)-box containing gene 9 (Sox9). In conclusion, high iron exposure 
can compromise chondrocyte metabolism which, when simultaneously affected by an Hfe 
loss of function, appear to be more susceptible to the establishment of an OA-related 
phenotype. 
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1-Introduction
Articular cartilage is a highly specialized tissue, avascular and hypocellular, 
composed primarily of water and extracellular matrix produced by chondrocytes, the only 
cell type present in this tissue [1]. Chondrocytes are specialized cells responsible for the 
production of extracellular cartilage matrix (ECM) composed by several macromolecules 
including aggrecan and type II, IX and XI collagens, which are important for the 
maintenance of the cartilage properties including tensile strength and flexibility [1, 2]. 
Osteoarthritis (OA) is the most frequent adult joint disease and is characterized by 
structural and molecular modifications in subchondral bone, synovial membrane, muscle, 
ligament and cartilage, that ultimately lead to joint destruction [3–5]. Several factors 
contribute to OA development including mechanical overload, ageing, genetic 
background, obesity, metabolic syndromes and the presence of calcium-containing 
microcrystals in the joint. However its underlying physiopathology is still incompletely 
understood [3–5].  
Hemochromatosis is an inherited metabolic disorder characterized by systemic 
iron overload and is associated to mutations in genes involved in iron metabolism [6, 7]. 
The most common gene affected is the HFE, encoding a protein that functions as an 
important sensor for systemic iron levels, the most prevalent HFE pathogenic mutation 
being the C282Y (p.Cys282Tyr) which results in the substitution of an adenine (A) for a 
cytosine (C), (NG_008720.2:g.10633G4A; NM_000410.3:c.845G4A), and individuals 
homozygotes for this mutation have an increased risk of developing iron overload. The 
association between OA and HFE-hemochromatosis was first  described by Schumacher 
in 1964, who showed an increased prevalence of arthritis in those patients [8]. Since then, 
several studies have confirmed this observation [9–14], which suggested an association 
between elevated iron concentrations, HFE loss of function and articular cartilage 
integrity, however it was not clear which could be the main factor affecting cartilage 
metabolism. Recently, we have shown that Hfe-KO mice develop more severe knee OA 
than wild type (WT) mice after joint destabilization induced by partial meniscectomy 
[14], but the underlying molecular mechanisms remain unclear. Therefore, we have 
developed an in vitro approach to further investigate the molecular events occurring in 
chondrocytes exposed to high levels of ferric citrate. Primary cultures of articular 
chondrocytes derived from Hfe-KO mice were exposed to 50 µM of ferric citrate in order 
to identify molecular factors and pathways involved in chondrocyte metabolism which 
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may contribute to OA onset and progression and, simultaneously, characterize the effect 
of Hfe loss of function in the regulation of intracellular iron accumulation. In addition, 
we investigated the effect of iron toxicity on chondrocyte catabolism by evaluating (i) the 
expression of genes and its targets associated to extracellular matrix degradation, and (ii) 
the expression of differentiation markers like osteocalcin (Bglap2) and SRY (Sex-
Determining Region Y)-box containing gene 9 (Sox9) [15]. By comparing the responses 
of Hfe-KO and WT chondrocytes subjected to similar experimental conditions, we 




All personnel involved in animal handling and experimentation received proper training 
(category B courses accredited by FELASA, the Federation of Laboratory Animal 
Science Associations). All experimental procedures involving animals followed the 
European Directive 2010/63/EU and the related guidelines (European Commission, 
2014). The University of Algarve animal facility was licensed by Portuguese National 
Authority for Animal Health (DGAV), within Portuguese legislation (DL 113/2013) for 
animal experimentation and welfare.
2.2-Biological models used in this study
Animals were maintained under pathogen-free conditions in individually 
ventilated cages at the University of Algarve animal facility under a 12hr light/dark cycle 
and with access to water and food (SDS RM3A, iron content 161 mg/kg) ad-libitum from 
weaning until euthanasia. The murine model of HH used in this study, Hfe-KO in a 
C57BL/6 background, was described by Bahram et al. (1999) [16] and backcrossed with 
C57BL/6 mice at IBMC. The Hfe-KO mice are homozygotes for a removal of exons 2 
and 3 of the HFE gene, leading to loss of function of the Hfe protein [16, 17].
2.3-WT and Hfe-KO primary chondrocytes isolation
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The method for isolation of primary chondrocytes was adapted from Gosset and 
colleagues (2008) [18]. In short, newborn mice (P6- day 6 after birth) were euthanized 
according with the recommendations of FELASA (Federation of European Laboratory 
Animal Science Associations). For isolation of articular cartilage, mouse anterior legs 
were dissected by removing the skin and soft tissues in order to isolate femoral heads and 
tibial plateau using a modular stereomicroscope (Leica MZ6). The articular cartilage 
pieces were submitted twice to 45 minutes incubation with 2mg/ml collagenase D (Gibco) 
solution followed by an overnight digestion with 0.5mg/ml of collagenase D (Gibco). All 
collagenase solutions were diluted in culture medium (Dulbecco’s modified Eagle’s 
medium (DMEM), (Gibco), supplemented with 1% Penicillin/Streptomycin (250 μg/ml, 
Gibco) and 1% Fungizone (250 μg/ml, Gibco).
Articular cartilage pieces were retrieved and passed sequentially through 25-, 10-, 5- and 
2-ml pipettes and filtered through a 40μm cell strainer (Fisherbrand, nylon mesh) 
followed by 2000g centrifugation for 10 minutes at room temperature. Cell pellets were 
resuspended in 10ml of culture medium supplemented with 10% Fetal Bovine Serum 
(FBS, Gibco). The chondrocyte suspension was counted in a hemocytometer and cell 
viability was determined by a quick trypan blue exclusion test (0.4%, Sigma). The 
isolated chondrocytes were seeded at 25,000 cells/cm2/well onto a 12 well culture dish 
and cultures (Sarstedt) allowed to reach confluence. From this point onward FBS 
supplemented medium was changed every two days.
2.4-Preparation of ferric citrate treatments
To determine the ferric citrate concentrations to be applied in primary culture of 
chondrocytes, a preliminary assay with several ferric citrate concentrations was 
performed (data not shown) and two concentrations were chosen: 10µM, which induced 
significant changes in iron metabolism markers, and 50µM, which induced not only iron 
metabolism changes but also chondrocyte metabolism alterations. In addition, the iron 
concentrations chosen were within the physiological range identified for Hfe-KO mice, 
which, in the presence of iron overload, showed total iron concentrations in plasma 
ranging between 30 and 60µM [19, 20].
Ferric citrate working solution was prepared from stock solutions of iron (III) 
chloride (10mM-Sigma-Aldrich), Trisodium citrate (100mM- Sigma-Aldrich) and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (1M-Sigma-Aldrich). Iron 
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citrate solution was applied to each well in dilutions of 1:33 in cell culture medium to 
reach final iron concentrations of 10 µM ([Fe-Cit 10 µM]) and 50 µM ([Fe-Cit 50 µM]). 
A negative control for iron presence was used by substituting the iron chloride solution 
by purified water (Sigma) [Na-Cit]. ferric citrate treatments were applied by adding it at 
each medium change, which occurred every two days, and evaluation for the effect of 
high ferric iron concentrations was done at days 7 (1 day after last treatment) and 10 (3 
days after last treatment) of culture.
2.5-Qualitative evaluation of extracellular cartilage matrix (ECM) production
The evaluation of ECM production was done by staining with alcian blue the 
primary chondrocyte cultures, which had been proliferating for 10 days in 12 well plates 
(Stardsted).. Before staining the cells, medium was removed, cells were rinsed with 
Phosphate-Buffered Saline (PBS: NaCl (137 mM), KCl (2.7 mM), Na2HPO42H2O (8.1 
mM), KH2PO4 (1.47 mM), Sigma-Aldrich) and fixated in 70% ethanol (Emplura, Merck) 
for 30 min at -20ºC. Then cells were rinsed 2x with PBS and incubated for at least 1hour 
with 1ml of 0.5% alcian blue (8GX-Sigma-Aldrich) dissolved in HCl (1M-Sigma-
Aldrich). After staining, each well was rinsed 2x with PBS and left in 1ml of PBS for 
analysis under a light-contrast microscope (Axiovert 25). Cell plates were photo-scanned 
and separated into three color channels (blue, green and red) for detection of pixel 
intensity of alcian blue staining using Image J. software v.151h (https://imagej.net/, 
RRID:SCR_003070) [21]. For each condition, three independent wells were evaluated 
and measured. 
2.6-Evaluation of expression of molecular markers 
RNA extractions of WT and Hfe-KO chondrocytes were done with High Pure 
RNA Isolation Kit (Roche) according with the manufacture instructions, which includes 
a DNase treatment during the procedure. For each condition tested, cells from three 
individual wells (Nucleon Delta Surface-Thermo scientific; 9.6cm2) were pooled and 
used for each RNA extraction. RNA samples were quantified, assessed for puritity using 
a Nanodrop 1000 (Thermo Scientific) and for integrity using the Experion system (Bio-
Rad). Then, 1μg of RNA from each condition tested was reverse transcribed using 1µL 
of oligo(dT) adapter primer (10 µM) and 1µL of M-MLV Reverse Transcriptase (1U/µL, 
Invitrogen) following manufacturer’s instructions. The qPCR reaction (20μl) was 
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performed using as template 2μl of 1:10 cDNA dilution (0.01μg) for each condition 
tested, 10µl of SsoFast Evagreen Taq supermix (BioRad), 0.6 µl of either target gene 
primers (300 nM) or housekeeping gene primers (300 nM), and the final volume 
completed with purified RNase-free water (Sigma). Amplification by qPCR was 
performed in a Step One Plus Realtime PCR System (Applied Biosystems). Results are 
from five different experiments. To determine the levels of gene expression, all results 
were normalized against Gapdh levels of expression and relative expression was 
determined by the ΔΔCt method [21] using as control group for basal expression cells 
without treatment, unless stated otherwise. All primer sequences are described in the 
supplementary data (Table A1).
2.7-Determination of intracellular iron
The evaluation of intracellular iron concentrations was only done at 10 days of 
culture when extracellular matrix production was significantly altered, in order to 
characterize the corresponding intracellular iron status.
Primary chondrocytes (WT and Hfe-KO) were isolated and cultured for 10 days 
in the presence of ferric citrate treatments to achieve concentrations of 10µM or 50 µM 
of iron, or in the absence of iron [Na-Cit]). Treatments were applied at each medium 
change. After 10 days, each cell culture plate was washed twice with PBS and treated 
with a solution of deferoxamine (DFO), (1mM-Sigma-Aldrich) in PBS for extracellular 
iron removal and then washed again with PBS. Quantification of intracellular iron 
concentrations was done with iron chelator Ferrozine (Sigma-Aldrich) using a method 
adapted from Riemer et.al. [22]. Briefly, 200µL of NaOH (50mM, Sigma Aldrich) were 
added to each well and cell plates were subjected to agitation for 2h under humidified 
atmosphere, after which cells were scrapped and 100µL of cell lysate recovered for iron 
quantification. To each 100µL of cell lysate were added 100µL of HCl (10mM) followed 
by 100µL of iron release solution (1:1; 4.5% KMnPO4 (Sigma-Aldrich):HCl 1.4M) and 
incubated for 2h at 60ºC. After this, 30µL of freshly prepared iron detection solution 
(Ferrozine (6.5mM), Cuproine (6.5mM), Acetate ammonium (2.5M) and Ascorbic acid 
(1M); all from Sigma-Aldrich) was added to each sample and 30 minutes later 280µL of 
the mix was removed and absorbance measured in a microplate reader (Synergy4) at 
550nm. The same procedure was done for calibration curve samples diluted in HCl 
(10mM). To normalize iron quantification the corresponding protein concentrations in 
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cell lysate were determined using the Bio-Rad Protein assay kit (Bio-Rad) according with 
manufacture recommendations. 
2.8- Evaluation of articular cartilage integrity by OARSI score  
WT and Hfe-KO mice (male and female) knee articulations were collected after 
euthanasia and fixed for 24h in 4% paraformaldehyde in PBS pH7.4, followed by 
decalcification with 0.5M Ethylenedinitrilotetraacetic acid (EDTA) in PBS pH 7.4 for 3 
weeks. Samples were then dehydrated with graded alcohols, cleared with Xylol and 
included in paraffin, followed by 5μm sagittal sectioning in a rotary microtome (Microm 
HM340E, Germany) and stained with Safranin-O/Fast Green/Meyer’s Hematoxylin. The 
evaluation was done in two sections per level and in three levels separated by 100µm 
each, starting at menisci separation. Two separate observers, blinded to the strain and type 
of intervention, graded the cartilage lesions using the semi-quantitative scoring system 
proposed by Glasson et al. 2010, also known as the OARSI scoring system for murine 
osteoarthritis. This system is based on the cartilage destruction extent, graded 0-6 
depending on the depth of the lesion and on the percentage of the articular surface 
affected. The score for each knee was the sum of the scores from each of the three levels. 
2.9-Western blot analysis
Isolated primary chondrocytes (WT and Hfe-KO) were maintained in culture and 
subject to iron citrate treatments ([Fe-Cit, 10 µM] and [Fe-Cit, 50 µM]) applied at each 
medium change for 10 days, or not treated ([NT]) for cells of control condition. For 
protein extracts isolation, each well (independent triplicates for each condition) was 
washed with cold PBS and cells were lysed using 200µl per well of lysis solution (50 mM 
Tris, 150 mM sodium chloride, 1% nonyl phenoxypolyethoxylethanol (NP-40), 10% 
glycerol, 10 mM magnesium chloride, 10 mM sodium orthovanadate (all reagents from 
Sigma-Aldrich), and protease inhibitor cocktail (Roche) and mechanically removed using 
cell scrapers (Sarstedt) followed by centrifugation of each sample for 15 min (15,000 g). 
Protein content in each sample was quantified by the Bio-Rad Protein Assay (Bio-Rad) 
and 35µg of protein for each condition were fractioned in 4–12% SDS/PAGE (Invitrogen) 
and transferred onto 0.45µm polyvinylidene difluoride (PVDF) membranes (Millipore, 
Billerica, MA, USA). Polyclonal anti-mouse rabbit antibodies were used for detection of 
MMP3 (1:500 dilution; Proteintech Group Cat# 17873-1-AP), and for normalization of 
expression, beta-Actin (1:500 dilution; Santa Cruz Biotechnology Cat# sc-47778), anti-
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rabbit IgG peroxidase conjugate (1:30,000 dilution; Sigma-Aldrich Cat# R3155) and anti-
mouse IgG peroxidase conjugate (1:30,000 dilution; Sigma-Aldrich Cat# A9044) were 
used. Peroxidase chemiluminescent signals were detected using the Western Lightning 
ECL kit (Perkin Elmer, Waltham, MA, USA).
2.10- In vivo ADAMTS5 and MMP3 imunohistochemistry detection
ADAMTS5 and MMP3 detection by immunohistochemistry were evaluated in 5 
µm sections from WT MNX and Hfe-KO MNX groups. The sections were dewaxed and 
rehydrated followed by epitope retrieval (for MMP3 with chondroitinase 0.1 UI/mL, 
C3667-Sigma-Aldrich, and for ADAMTS5 with 10% Trypsin-EDTA solution, Sigma-
Aldrich), and then treated with 3% hydrogen peroxide to block endogenous peroxidases 
for 10min. Next the sections were incubated for 30 min with blocking solution (6% horse 
serum (Sigma-Aldrich) and 4% BSA) prior to incubation with polyclonal rabbit 
antibodies against mouse MMP-3 (AB53015, Abcam at 1:100 in 3% horse serum and 2% 
BSA) and ADAMTS-5 (Ab39202, at 1:50 in 3% horse serum and 2% BSA) at 4ºC 
overnight. The sections were next incubated with the secondary antibody (horseradish 
peroxidase-conjugated goat antibodies against rabbit IgG (Vector MP-7401)) at a 1:100 
dilution and revelation done with DAB Kit SK4100 (Vector laboratories). 
Counterstaining was done with 1% methyl green (Sigma-Aldrich), which stains hyaline 
cartilage tissues. 
2.11-Statistical analysis
Unless stated otherwise, results are expressed as the mean and standard deviation 
(SD). Each group was evaluated for normality with Kolmogorov-Smirnov test and 
confirmed for application of parametric analysis. Comparisons of matrices of means in 
function of iron citrate treatments versus mice genotypes were done by Two-way 
ANOVA. Multiple comparisons in both statistical tests used were done by Tukey method 
with p<0.05. Indications of significance for multiple tests were subdivided into (a) and 
(b) for comparison within the same genotype: (a)- when differences in results were 
significant compared to iron citrate treatment control group ([Na-Cit]) and (b) when 
differences in results were significant compared to 10 µM iron citrate treatment ([Fe-Cit 
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10 µM]); (*)- Significance of Hfe-KO genotype relative to WT when subject to the same 
iron citrate treatments. For data where normality was not confirmed, Krustal-Wallis test 
was done with Dunn’s post-hoc test for multiple comparison. For comparison of data 
where normality was confirmed, the One-way ANOVA was used with Tukey test for 
post-hoc multiple comparison with p<0.05. 
3-Results
3.1 Hfe-KO primary chondrocyte cultures morphology and molecular phenotype 
Primary chondrocytes were isolated from the articular cartilage of the knee joint 
from Hfe-KO and WT newborn mice and its morphological, histological and molecular 
profiles analyzed. In terms of morphology, no significant differences were observed, with 
cells showing the typical hexagonal phenotype of chondrocytes (Supplementary figure 
S1-A). The expression of molecular markers for chondrocyte metabolism was determined 
in WT and Hfe-KO primary chondrocytes by qPCR. Both cells expressed similar levels 
of transcripts for collagens type I, II and X (Col1a1, Col2a1, Col10a1) and for aggrecan 
(Acan), with the expression of Col2a1 transcripts being predominant. Expression of 
transcription factor AP-2-alpha (Tfap2a), a negative marker of chondrocyte 
differentiation, was nearly absent in both cell cultures, as expected (Supplementary figure 
S1-B). Viability was assessed for both WT and Hfe-KO cells treated with 10 µM and 50 
µM of ferric citrate during 72h and 120h. Chondrocyte viability was similar in both 
genotypes and was not affected by iron treatment (Supplementary figure S2). The results 
were confirmed in vivo (Figure 2) as Hfe-KO mice did not spontaneously develop an early 
OA phenotype. Results showed no significant lesions or loss of cartilage in Hfe-KO mice 
knee articulation with 12 months of age. In addition, accumulation of iron deposits was 
not observed in the articular cartilage, only in subchondral bone (Figure 2-C).
3.2-Hfe-KO chondrocytes show imbalanced iron metabolism 
WT and Hfe-KO chondrocytes showed similar profiles for Slc40a1 and Fht1 gene 
expression in response to excess iron (10 and 50 µM of ferric citrate exposure). Both 
Slc40a1 and Fht1 were upregulated (Figure 1-A) with a significant increase observed in 
cells Hfe-KO relative to WT when exposed to 50 µM of ferric citrate (Figure 1-A). In 
Page 10 of 34BioFactors
11
response to excess iron, Tfrc receptor was downregulated in WT but not in Hfe-KO cells 
(Figure 1-A), indicative of an intracellular iron transport inhibition for WT which was not 
observed in Hfe-KO chondrocytes. These results were confirmed by the anaysis of 
intracellular iron levels in WT and Hfe-KO chondrocytes at 10 days of incubation, when 
the effect of iron in ECM degradation was evident. The results showed a significant 
increase of intracellular iron in cells Hfe-KO relative to WT subject to 50 µM of ferric 
citrate (Figure 1-B). This accumulation of iron was not linearly correlated, which 
suggested that both WT and Hfe-KO chondrocytes were able to regulate iron entry, 
although less efficiently in Hfe-KO genotype. This is in agreement with results obtained 
when comparing the expression of iron transporters, Tfr2 and Slc39a14, in response to 10 
µM and 50 µM of ferric citrate. Both were downregulated in 50 µM-treated cells relative 
to those treated with 10 µM (Figure 1-C). In addition, for both WT and Hfe-KO cells, 
Bmp6, the main iron metabolism regulator, showed a pathern of expression similar to 
those of iron transporters, being upregulated in response to 10 µM treatment, but returning 
to control levels in the presence of 50 µM treatment (Suplementary figure S3). 
3.4-Inflammatory and antioxidant response to increased iron concentrations
Because inflammatory pathways have been associated to onset of OA phenotype, 
the expression of interleukin-1-beta (Il-1b) and interleukin-6 (Il-6) were evaluated in the 
WT and Hfe-KO chondrocytes treated with iron citrate, after 7 days in culture. No 
significant changes in the expression of Il-1b and Il-6 were observed at the analysed time 
points, (Supplementary figure S4). These results were confirmed for chondrocytes treated 
with 50 µM at 10 days of incubation (data not showed). To evaluate the antioxidant 
response in this in vitro system, expression of Catalase (Cat) and Cu/Zn superoxide 
dismutase (Sod) transcripts was analysed in WT and Hfe-KO cells. Both showed a 
significant increase in Cat expression in response to 50 µM of ferric citrate treatments 
(Figure 3-A). In contrast, no differences were observed in the expression of Sod (data not 
shown). The expression of endothelial PAS domain-containing protein 1 (Epas1), also 
known as hypoxia-inducible factor 2-alpha (Hif-2-alpha), a transcription factor associated 
with hypoxia and antioxidative response and a catabolic regulator of cartilage destruction, 
showed a similar trend of expression, with higher expression levels observed under 50 
µM treatment for both WT and Hfe-KO cells (Figure 3-B).
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3.5-Effect of ferric citrate treatments on expression of chondrocyte metabolic 
markers 
The expression of three genes associated with chondrocyte catabolism (Mmp3, 
Mmp13 and Adamts5) was evaluated. A similar pattern of gene expression was observed 
for Mmp13 and Adamts5, both in WT and Hfe-KO chondrocytes, with a clear 
upregulation always observed upon treatment with 50 µM of iron (Figure 3-C). 
Expression of genes related to chondrocyte anabolism (Col1a1, Cola10a1 and Acan) also 
showed, in each case, a similar pattern for both WT and Hfe-KO cells (Figure 4-A) 
indicating a similar mode of regulation in the presence 50 µM of iron . We have also 
analysed the expression of Runx2 but no significant differences were found under 10 µM 
and 50 µM treatments in both WT and Hfe-KO cells, (data not shown). Treatments with 
50 µM of ferric citrate also affected chondrocyte differentiation markers similarly for WT 
and Hfe-KO cells, with increased expression of osteocalcin (Bglap2) and transferrin (Trf) 
and a concomitant decrease in expression of SRY (Sex-Determining Region Y)-box 
containing gene 9 (Sox9), (Figure 4-B).
3.6-High iron concentrations promoted a significant decrease in proteoglycan 
production
As iron treatment appeared to be modulating in a similar way the expression of 
proteolytic enzymes and anabolic markers in both WT and Hfe-KO chondrocytes, we 
assessed whether it could modify the proteoglycan content of the cultures. Cells were 
stained with alcian blue and analysed after 7 and 10-day treatments with the 2 different 
concentrations of ferric citrate. Significant changes were only detected after 10 days. Both 
WT and Hfe-KO chondrocytes treated with 50 µM of ferric citrate showed significant 
decrease in alcian blue staining compared to untreated chondrocytes (Figure 5-B). These 
results were in agreement with the changes observed in expression of genes associated to 
chondrocyte catabolism for the same iron concentrations (50 µM of ferric citrate, Figure 
3), a result which was confirmed at the level of protein for MMP3 (Figure 5-C). In 
addition, an increase in protein expression was observed for ADAMTS5 and MMP3 in 
Hfe-KO samples when compared to WT (Figure 6). These results confirmed data 
previously described by our group in Camacho et al. (2016).
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4-Discussion
HFE protein is a known molecular player in iron metabolism, with impact on the 
regulation of intracellular iron concentrations and hepcidin expression in liver tissue [17, 
23]. Attending to the increased incidence of osteoarthritis associated with HFE- 
hemochromatosis [24–26], our primary objective was to investigate the effect of Hfe loss 
of function on chondrocyte metabolism. For that we have done a molecular 
characterization of WT and Hfe-KO primary chondrocyte cultures. We have first 
evaluated the effect of Hfe loss of function on cell phenotype and marker gene expression 
in primary cultures of chondrocytes from Hfe-KO mice and compared with data from WT 
derived cultures. Primary cultures of Hfe-WT or KO chondrocytes revealed their typical 
phenotype, comparable to previous reports [18, 27]. As expected, the expression of 
Col2a1 was preponderant and those of Col1a1 and Col10a1 were low (Supplementary 
figure S1-B), in agreement with previous works [18, 28]. In addition, Hfe-KO cells 
expressed Acan, a marker for extracellular matrix production [18], at levels similar to 
those found in WT cells, while there was no expression of Tfap2a, a negative marker of 
chondrocyte differentiation [28] (Supplementary figure S1-B). Thus, absence of Hfe did 
not alter the typical chondrocyte phenotype. These results suggest that the presence of a 
mutated Hfe gene alone was not sufficient to induce an OA-like phenotype in 
chondrocytes. Accordingly, we have shown in vivo that Hfe-KO mice did not develop 
OA (Figure2). 
The absence of significant iron deposits in the Hfe-KO mice articular cartilage 
(Figure 2-C), suggests that an additional insult to articular cartilage is required to develop 
a pathological phenotype, in agreement with our previous data [14]. This was 
demonstrated in mice subject to meniscus destabilization, namely the aggravation of OA 
phenotype in Hfe-KO mice when compared with WT group (Figure 6-A), with evidences 
of significant iron accumulation in synovial tissues of Hfe-KO mice[14]. HFE effect on 
iron overload is connected with the downregulation of hepcidin expression (mainly 
specific to liver), which can favour dietary iron absorption and ferroportin iron 
exportation to plasma, resulting in systemic iron overload [29–31]. In addition, HFE loss 
of function can lead to increased intracellular iron absorption [32, 33]. The fact that 
articular cartilage is an avascular tissue [1] suggests that HFE can only contribute to OA 
progression if articular cartilage is exposed to blood, where it is possible to find both iron 
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bound (TBI) and non-bound (NTBI) to transferrin. This is expected in HFE-
hemochromatosis patients following a trauma event and/or lesion in the articulation 
associated with bleeding and the corresponding increase in iron exposure. 
Because it is known that HFE-hemochromatosis leads to a progressive iron 
overload with time [34], we designed experiments using concentrations close to 
physiological iron overload conditions (50µM) [19, 20] to investigate if that would lead 
to the establishment of an OA-like phenotype. We submitted primary chondrocyte 
cultures (WT and Hfe-KO) to 10 µM and 50 µM of ferric citrate and results obtained 
showed that both WT and Hfe-KO chondrocytes developed an OA-like phenotype 
without mechanical or inflammatory stimulus. When cultured for 7 and 10 days under 10 
µM and 50 µM of ferric citrate, both Hfe-KO and WT cells showed significant changes 
in gene expression in response to treatment (Figure 1-A and Supplementary figure S6). 
The molecular profile was indicative of increased iron accumulation, which was more 
accentuated in Hfe-KO chondrocytes treated with 50 µM of ferric citrate. These results 
were confirmed by the observed significant increase in the levels of intracellular iron 
concentrations (Figure 1-B). The upregulation of Fth1 and Slc40a1 (Figures 1-A and 
Supplementary figure S6) suggested an increase in the molecular response to intracellular 
iron in excess and an increase in iron export respectively, resulting from an attempt to 
reduce intracellular iron labile pool and contribute to iron detoxification, in agreement 
with previously published data [34–36]. 
Intracellular levels of iron accumulation did not present a linear correlation with 
levels of ferric citrate treatments (Figure 1-B), suggesting that intracellular iron regulation 
can be explained not only by an increase in Slc40a1 expression (Figures 1-A and 
Supplementary figure S6), to export excess iron, but also by the downregulation of Tfrc 
in WT chondrocytes (Figure 1-A) in agreement with previous data [37, 38]. In Hfe-KO 
chondrocytes, levels of intracellular iron were significantly higher than in WT cells when 
subject to 50 µM of ferric citrate (Figure 1-B). This suggests a deregulation in the 
mechanism of iron import in those cells, probably related to the absence of a functional 
HFE protein, known to play an essential role in the regulation of iron transport into the 
cells by competing with TRF for TFRC binding [23]. If TRF binds to TFRC, it promotes 
the internalization of TFRC/TRF complex along with solute carrier family 11 member 2 
(SLC11A2, also known as DMT-1) leading to intracellular iron absorption [39]. In this 
study, Tfrc was not significantly downregulated in Hfe-KO chondrocytes, in contrast to 
results in WT cells (Figure 1-A). Because SLC11A2 is a key player in intracellular iron 
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uptake following TFRC/TRF internalization, the absence of a functional HFE could 
favour intracellular iron accumulation since it was previously shown that HFE/β2-
microglobin complex is able to colocalize and bind with SLC11A2 and inhibit iron 
absorption [40]. However, regarding NTBI cellular uptake it was showed that SLC11A2 
was not able to impair NTBI absorption in the liver enterocytes only transferrin bound 
iron (TBI) [41], contrarily to what was observed in enterocytes [36]. SLC11A2 is a 
ferrous iron transporter [39], and the treatment was done with ferric citrate, which 
suggests that the iron uptake may be done through TFRC/TRF internalization with the 
influence of HFE, unless pH and/or oxygen levels decrease. In addition, we have analyse 
the expression of Slc39a14, known NTBI intracellular transporter [42], was possible to 
observe that Slc39a14 was upregulated when cells were subject to 10 µM of ferric citrate, 
however upon 50 µM treatment Slc39a14 return to basal expression (Figure 1-C), 
suggesting a response to inhibit iron uptake and without the influence of HFE.
Since hepcidin expression was only detected at residual levels (data not shown), 
this led us to hypothesize that the significant differences observed in response to iron 
metabolism markers in Hfe-KO chondrocytes relative to WT should be primarily 
connected with the absence of HFE protein, responsible for regulating the entry of iron 
inside the cells [36, 43], and not with the regulation of ferroportin (SLC40A1) degradation 
by hepcidin [34, 44]. The absence of an increased expression of inflammatory markers in 
both WT and Hfe-KO cells in this study was also previously observed during OA 
progression in Hfe-KO mice [14], and may be connected with primary response to stress, 
as also described previously in a blood induced joint damage study [45]. In that study, 
upregulation of Il-1b and Il-6 occurred only in the first hours after bleeding stimuli, and 
the levels of inflammatory markers decreased to basal levels after 24h, which could 
explain why we did not observe significant changes in the expression of pro-inflammatory 
markers, given the fact that we only analysed gene expression 24h and 72h after the last 
treatment. It will therefore be important in the future to study the inflammatory response 
in chondrocyte cultures in the first hours after ferric citrate treatment to understand the 
impact of inflammation in this context.
Increased ROS concentrations have been associated with OA phenotype [46, 47] 
which led us to evaluate indirect evidences of oxidative stress by analysing the expression 
of molecular markers associated with antioxidant response, like Cat, which showed to be 
upregulated in both WT and Hfe-KO cells (Figure 3-A). These results suggested that iron 
overload promoted an antioxidant response in chondrocytes [48, 49]. Another marker 
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known to be sensitive to iron availability is Epas1, which is associated with hypoxia [50, 
51] and one important catabolic regulator of cartilage destruction [52]. Our results show 
significant upregulation of Epas1 in response to the higher ferric citrate treatment (50 
µM) (Figure 3-B) suggesting that Epas1 should be contributing for the establishment of 
OA phenotype on both WT and Hfe-KO chondrocytes.
Bmp6, besides being one of the main regulators of hepcidin and of iron 
metabolism [53–55], has also been shown to be an inducer of chondrocyte proliferation 
and ECM production [56, 57]. The results for Bmp6 expression (supplementary figure 
S3) suggested that, after an initial response to iron increase (10µM) in WT and Hfe-KO 
chondrocytes, and upon higher iron concentrations, Bmp6 expression was restrained. This 
was indicative of a decrease in the SMAD 1, 5 and 8 pathway [53, 58], and reported to 
donwregulate Col10a1 and Sox9 and increase col1a1 and bglap2 [59], which is in 
agreement with what we observed (Figure 4). Ferric citrate treatments had a significant 
and similar impact in the expression of Col1a1, Col10a1 and Acan in WT and Hfe-KO 
chondrocytes (Figure 4-A), as previouly observed and already associated with OA onset 
and progression in several in vivo and in vitro studies [14, 60–62]. 
In OA, the expression of Col10a1 has been mostly shown to be increased [14, 60, 
62], however downregulation of Col10a1 in human OA-associated articular chondrocytes 
has also been reported [61], similar to the gene expression pattern found in our study for 
Hfe-KO chondrocytes (Figure 4-A). Accordingly, upregulation of Bglap2 and 
downregulation of Sox9 in Hfe-KO chondrocytes (Figure 4-B) are in agreement with data 
reported previoulsy and shown to be associated with OA phenotypes [63–65], thus 
contributing to the significant impact of iron in chondrocyte differentiation towards 
hypertrophy. In addition, expression of the runt related transcription factor 2 (Runx2), an 
important transcription factor associated with chondrocytes hypertrophy [64], was not 
significantly changed by ferric citrate treatments (results not shown), whicht could 
explain the absence of Col10a1 upregulation in this context and suggests the existence of 
an alternative mechanism to induce an hypertrophy-like phenotype in WT and Hfe-KO 
chondrocytes subjet to 50 µM of ferric citrate. Indeed, Trf expression was significantly 
upregulated (Figure 4-B). Since this increase in expression has not been directly 
associated with an iron increase [66], it could be associated with the acceleration of 
chondrocyte differentiation process towards an hypertrophy-like phenotype, an 
hypothesis that remains to be further explored, however this response could favour 
intracellular iron uptake through TRF/TFRC complex in the absence of a functional HFE.
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The evaluation of WT and Hfe-KO chondrocytes catabolism showed that 
expression of metalloproteases (Mmp3, Mmp13 and Adamts5) was significantly altered 
in the presence of a 50 µM iron treatment (Figures 3-C, 5-C), in agreement with 
previously reported evidences for upregulation of metalloproteases upon 100 µM FeCl2 
exposure [67]. In addition, extracellular matrix was significantly affected throughout 
progressive iron overload exposure, both in Hfe-KO and WT chondrocytes (Figure 5-A). 
These results were also confirmed by the in vivo increase in MMP3 and ADAMTS5 
(Figure 6) and consequent decrease in methyl green staining (to detect hyaline cartilage 
[68]) in Hfe-KO mice subject to MNX relative to WT MNX animals, also observed in 
our previous work [14]. The significant upregulation of Mmp3 found in Hfe-KO 
chondrocytes suggests a possible synergistic effect between iron overload exposure and 
HFE loss of function. Altogether, these results are in agreement with published data since 
increase in MMP3 protein expression was previously associated to osteoarthritis 
phenotype and to extracellular matrix degradation [62, 67] and suggest that iron overload 
conditions had a decisive impact in the catabolic activity of chondrocytes. The Hfe-KO 
chondrocyte genotype revealed increased susceptibility for deregulation of iron 
metabolism and related changes in gene expression, similarly to what may be happening 
during OA progression and with the association in vivo of mutations in Hfe with 
dysregulation of iron metabolism, which appear to contribute to increase OA phenotype 
[14]. However, results for WT chondrocytes showed that iron overload exposure was 
enough to produce an OA phenotype and ECM degradation with similar impact on gene 
expression markers. This finding suggested that HFE-hemochromatosis related OA 
establishment is conditioned by systemic iron overload produced by the impact of Hfe 
loss of function on liver hepcidin expression [17] and on chondrocyte metabolism, which 
can become relevant if articular cartilage is exposed to iron overload conditions attending 
to its role on the regulation of intracellular iron import [17, 23]. 
The exposure of WT and Hfe-KO chondrocytes to ferric citrate loads favoured 
iron accumulation and the development of an OA-similar phenotype, which is in 
agreement to what was described previously with the identification of iron deposits in the 
articular cartilage and synovial membrane of HFE-hemochromatosis patients and 
cartilage associated degradation [69–71]. Iron deposits were also detected in thalassemia 
patients articulation [72], suggesting the putative toxic effect of iron overload inside 
articulations. Epidemiology studies report high prevalence of OA associated HFE-
hemochromatosis in patients averaging 60 years of age, with a strong association between 
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transferrin saturation and serum ferritin concentrations [26, 73]. Evidences showed that 
iron overload should play an important role on OA progression in HFE-hemochromatosis 
patients [14, 26]. In addition, these patients showed higher susceptibility for the 
prevalence of OA when compared with non-HFE-hemochromatosis patients [74], which 
suggests additional susceptibility beyond systemic iron overload. Recently, it was 
reported a case were an HFE-hemochromatosis patient showed an early onset of knee OA 
(since he was 18 years old) [75]. The patient systemic iron parameters were considered 
normal even with constant OA related complains, however before the patient underwent 
bilateral knee replacement, significant iron deposits were observed in the knee synovial 
membrane [75], which may suggest a susceptibility associated with iron accumulation in 
synovium. Accordingly, the absence of HFE in cells cytoplasmatic membrane as 
consequence of pC282Y substitution [76] were previously shown to favor intracellular 
iron accumulation [33]. In addition, attending that HFE is a protein belonging to the major 
histocompatibility complex (MHC-I) family, we cannot exclude that OA associated HFE-
hemochromatosis could  also be related with a possible immune response to the absence 
of pC282Y HFE in cytoplasmic membrane [77]. There is also a report in which hand 
osteoarthritis prevalence is increased in heterozygotes (pC282Y) [11], however a recent 
study showed no significand differences between the prevalence of OA in pC282Y 
heterozygotes compared to general population [78]. Therefore, further studies regarding 
HFE recognition by the immune system are required. 
In conclusion, exposure of WT and Hfe-KO chondrocyte cultures to high iron 
concentrations promoted the establishment of an OA-like phenotype suggesting that high 
levels of iron can contribute to the progression of OA associated with HFE- 
hemochromatosis. In addition, results suggest that Hfe loss of function can contribute to 
promote an increase in intracellular iron accumulation in primary chondrocytes. 
However, this study cannot exclude the hypothesis that the onset of OA associated with 
HFE-hemochromatosis could be related with acute immune responses, even if the levels 
of inflammation are not comparable with those observed in chronic inflammation diseases 
like rheumatoid arthritis [70]. We propose that, upon articular lesion and/or trauma, 
patients showing systemic iron overload can present a degradation of articular cartilage 
associated with an increase in osteoarthritis progression. Our study does not take into 
account possible interactions between articular cartilage and synovial tissues since, 
accordingly with several reports, synovial membrane presents high levels of iron deposits 
in HFE-hemochromatosis [70, 75], which we also observed previously in Hfe-KO mice 
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with aggravated OA progression [14]. Additional studies should be made regarding this 
possible interaction and the onset of OA in HFE-hemochromatosis.
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Figures legends 
Figure 1- Expression of genes associated with iron metabolism in Hfe-KO and WT 
chondrocytes cultured under iron overload conditions (Genes: Solute Carrier Family 40 
Member 1 (Slc40a1), also known as ferroportin, Ferritin Heavy Chain 1 (Fth1), solute 
carrier family 39 (zinc transporter) member 14 (Slc39a14), Transferrin receptor 1 (Tfrc) 
and Transferrin receptor 2 (Tfr2)). Cells were cultured for 7 days in the presence of either 
10 μM or 50 μM of ferric citrate, or vehicle ([Na-Cit]). Results shown correspond to 
relative expression normalized with Gapdh from n=5 pools of three cell culture wells 
(9.6cm2) for each genotype (WT and Hfe-KO). Each pool corresponded to an independent 
experiment; A)-Intracellular iron markers (Slc40a1, Fth1 and Tfrc), B)- Correlation 
between measured intracellular iron concentrations and levels of ferric citrate treatments 
applied to WT and Hfe-KO chondrocytes. Each condition corresponded to data from n=3 
samples and were expressed as mean +/- standard deviation (SD). (C)- Iron transporters 
(Tfr2, Slc39a14); Statistical analysis was done by Two-way ANOVA, followed by Tukey 
multiple comparison test with p<0.05. Statistical significance: (a)- compared to control 
[Na-Cit]; (b)- compared to [Fe-Cit 10 µM]); (*)- comparison between WT and Hfe-KO 
cells subject to [Fe-Cit 50 µM].
Figure 2-Articular cartilage integrity analysis and iron status in Hfe-KO mice A- 
Evaluation of knee articular cartilage integrity through OARSI score of WT and Hfe-KO 
mice with 12 months of age (male (n=7) and female (n=4)) and examples of articular 
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cartilage phenotype in 5μm sagittal sections of WT and Hfe-KO mice stained with 
Haematoxylin-Fast Green-Safranin-O staining. (*) Statistical significance with p<0.05. 
Comparison was made T-test within each genotype B- Total serum iron quantification 
from WT and Hfe-KO male mice with 12 months of age. C- Perls staining of 
undecalcified tissues sagittal sections (5μm) of articular cartilage included in Methyl 
methacrylate (MMA). Iron deposition shown by dark blue staining.
Figure 3- Expression of genes associated with antioxidant response, hypoxia and markers 
associated with chondrocyte catabolism. Hfe-KO and WT chondrocytes were subjected 
to treatments for 7 days with either 10μM or 50μM of ferric citrate, or vehicle ([Na-Cit]). 
Results were normalized with Gapdh from n=5 pools of three cell culture wells (9.6cm2) 
for each genotype (WT and Hfe-KO). Each pool corresponded to one independent 
experiment; A)- Antioxidant response (Cat); B)-Hypoxia (Epas1); C) Chondrocyte 
catabolism- (Mmp3, Mmp13 and Adamts5). Statistical analysis was done by Two-way 
ANOVA followed by Tukey multiple comparison test with p<0.05; Statistical 
significance: (a)- compared to control [Na-Cit]; (b)- compared to [Fe-Cit 10 µM]); (*)- 
comparison between WT and Hfe-KO cells subject to [Fe-Cit 50 µM]. 
Figure 4- Expression of genes associated with chondrocyte metabolism. Expression of 
A)-Markers for chondrocyte anabolism (Col1a1, Col10a1 and Acan); and B)-Markers for 
transdifferentiation (Bglap2, Sox9 and Trf), were analysed in WT and Hfe-KO 
chondrocytes after 7 days in culture treated with either 10 μM or 50 μM ferric citrate, or 
in vehicle ([Na-Cit]); Results are from n=5 pools of three cell culture wells (9.6cm2) for 
each genotype (WT and Hfe-KO).Each pool corresponded to one independent 
experiment. All results were normalized by Gapdh and statistical analysis was done by 
Two-way ANOVA followed by Tukey multiple comparison test with p<0.05; Statistical 
significance: (a)- compared to control [Na-Cit]; (b)- compared to [Fe-Cit 10 µM]); For 
Bglap2 expression WT groups did not show a normal distribution, therefore multiple 
comparison between treatments WT chondrocytes was done by Kristal-Wallis method 
and multiple comparison with Dunn’s post-hoc test. For Hfe-KO chondrocytes One-way 
ANOVA was used to compare the impact of treatments with control, with Tukey test for 
post-hoc multiple comparison with p<0.05.
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Figure 5- Evaluation of extracellular matrix degradation in WT and Hfe-KO 
chondrocytes. A) Comparison of Alcian blue staining relative pixel intensity in 
chondrocytes treated with 50 µM of ferric citrate relative to vehicle ([Na-Cit]. B) WT and 
Hfe-KO chondrocytes stained with Alcian blue. Statistical analysis was done by T-test, 
with p<0.05. Statistical significance: (a)- compared to control [Na-Cit]. C)- Levels of 
MMP3 in WT and Hfe-KO chondrocytes cultured for 10 days detected by Western blot 
and peroxidase chemiluminescent signals compared to levels of beta actin as described in 
materials and methods section. Results correspond to the levels of protein from a pool of 
wells obtained from three independent experiments. 
Figure 6-Expression of MMP3 and ADAMTS5 in WT and Hfe-KO mice subject to knee 
destabilization. A- Articular cartilage integrity analysis. Evaluation of knee articular 
cartilage integrity detected through OARSI score in WT (Sham and MNX) and Hfe-KO 
(Sham and MNX) mice. (n=10). Results described are a result of the summed OARSI 
score average between the three levels evaluated in the articular cartilage of each mice by 
two independent observers. The associated error is the confidence interval at 95%. 
Statistical analysis was done by Two-way ANOVA, followed by Tukey multiple 
comparison test with p<0.05 for each group analysed (WT sham, WT MNX, Hfe-KO 
Sham and Hfe-KO MNX) in tibia and femur. Comparisons between tibia and femur 
results were done by Paired T-test with p<0.05 for significance. a) statistical significance 
with p<0.05 between Sham and MNX groups within each genotype. b) Statistical 
significance between WT MNX and Hfe-KO MNX with p<0.05. * Statistical significance 
between tibia and femur with p<0.05. B- Detection of disintegrin and metallopeptidase 
with thrombospondin motifs (ADAMTS-5) and matrix metallopeptidase 3 (MMP-3) in 
articular cartilage.- Immunohistochemistry for knee articular cartilage in tibia of control 
(WT MNX) and Hfe-KO (Hfe-KO MNX) mice at 8 weeks after MNX surgery. 
ADAMTS5 and MMP3 detection was done with DAB Kit SK4100 and correspond to 
brown staining. Counterstaining was done with 1% methyl green, which stains hyaline 
cartilage tissues. The comparison between WT and Hfe-KO showed higher degree of 
ADAMTS5 and MMP3 detection in Hfe-KO mice relative to WT.
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Figure 1- Expression of genes associated with iron metabolism in Hfe-KO and WT chondrocytes cultured 
under iron overload conditions (Genes: Solute Carrier Family 40 Member 1 (Slc40a1), also known as 
ferroportin, Ferritin Heavy Chain 1 (Fth1), solute carrier family 39 (zinc transporter) member 14 (Slc39a14), 
Transferrin receptor 1 (Tfrc) and Transferrin receptor 2 (Tfr2)). Cells were cultured for 7 days in the 
presence of either 10 μM or 50 μM of ferric citrate, or vehicle ([Na-Cit]). Results shown correspond to 
relative expression normalized with Gapdh from n=5 pools of three cell culture wells (9.6cm2) for each 
genotype (WT and Hfe-KO). Each pool corresponded to an independent experiment; A)-Intracellular iron 
markers (Slc40a1, Fth1 and Tfrc), B)- Correlation between measured intracellular iron concentrations and 
levels of ferric citrate treatments applied to WT and Hfe-KO chondrocytes. Each condition corresponded to 
data from n=3 samples and were expressed as mean +/- standard deviation (SD). (C)- Iron transporters 
(Tfr2, Slc39a14); Statistical analysis was done by Two-way ANOVA, followed by Tukey multiple comparison 
test with p<0.05. Statistical significance: (a)- compared to control [Na-Cit]; (b)- compared to [Fe-Cit 10 
µM]); (*)- comparison between WT and Hfe-KO cells subject to [Fe-Cit 50 µM]. 
338x190mm (96 x 96 DPI) 
Page 29 of 34 BioFactors
 
Figure 2-Articular cartilage integrity analysis and iron status in Hfe-KO mice A- Evaluation of knee articular 
cartilage integrity through OARSI score of WT and Hfe-KO mice with 12 months of age (male (n=7) and 
female (n=4)) and examples of articular cartilage phenotype in 5μm sagittal sections of WT and Hfe-KO 
mice stained with Haematoxylin-Fast Green-Safranin-O staining. (*) Statistical significance with p<0.05. 
Comparison was made T-test within each genotype B- Total serum iron quantification from WT and Hfe-KO 
male mice with 12 months of age. C- Perls staining of undecalcified tissues sagittal sections (5μm) of 
articular cartilage included in Methyl methacrylate (MMA). Iron deposition shown by dark blue staining. 
338x190mm (96 x 96 DPI) 
Page 30 of 34BioFactors
 
Figure 3- Expression of genes associated with antioxidant response, hypoxia and markers associated with 
chondrocyte catabolism. Hfe-KO and WT chondrocytes were subjected to treatments for 7 days with either 
10μM or 50μM of ferric citrate, or vehicle ([Na-Cit]). Results were normalized with Gapdh from n=5 pools of 
three cell culture wells (9.6cm2) for each genotype (WT and Hfe-KO). Each pool corresponded to one 
independent experiment; A)- Antioxidant response (Cat); B)-Hypoxia (Epas1); C) Chondrocyte catabolism- 
(Mmp3, Mmp13 and Adamts5). Statistical analysis was done by Two-way ANOVA followed by Tukey multiple 
comparison test with p<0.05; Statistical significance: (a)- compared to control [Na-Cit]; (b)- compared to 
[Fe-Cit 10 µM]); (*)- comparison between WT and Hfe-KO cells subject to [Fe-Cit 50 µM]. 
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Figure 4- Expression of genes associated with chondrocyte metabolism. Expression of A)-Markers for 
chondrocyte anabolism (Col1a1, Col10a1 and Acan); and B)-Markers for transdifferentiation (Bglap2, Sox9 
and Trf), were analysed in WT and Hfe-KO chondrocytes after 7 days in culture treated with either 10 μM or 
50 μM iron citrate, or in vehicle ([Na-Cit]); Results are from n=5 pools of three cell culture wells (9.6cm2) 
for each genotype (WT and Hfe-KO).Each pool corresponded to one independent experiment. All results 
were normalized by Gapdh and statistical analysis was done by Two-way ANOVA followed by Tukey multiple 
comparison test with p<0.05; Statistical significance: (a)- compared to control [Na-Cit]; (b)- compared to 
[Fe-Cit 10 µM]); For Bglap2 expression WT groups did not show a normal distribution, therefore multiple 
comparison between treatments WT chondrocytes was done by Kristal-Wallis method and multiple 
comparison with Dunn’s post-hoc test. For Hfe-KO chondrocytes One-way ANOVA was used to compare the 
impact of treatments with control, with Tukey test for post-hoc multiple comparison with p<0.05. 
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Figure 5- Evaluation of extracellular matrix degradation in WT and Hfe-KO chondrocytes. A) Comparison of 
Alcian blue staining relative pixel intensity in chondrocytes treated with 50 µM of iron citrate relative to 
vehicle ([Na-Cit]. B) WT and Hfe-KO chondrocytes stained with Alcian blue. Statistical analysis was done by 
T-test, with p<0.05. Statistical significance: (a)- compared to control [Na-Cit]. C)- Levels of MMP3 in WT 
and Hfe-KO chondrocytes cultured for 10 days detected by Western blot and peroxidase chemiluminescent 
signals compared to levels of beta actin as described in materials and methods section. Results correspond 
to the levels of protein from a pool of wells obtained from three independent experiments. 
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Figure 6-Expression of MMP3 and ADAMTS5 in WT and Hfe-KO mice subject to knee destabilization. A- 
Articular cartilage integrity analysis. Evaluation of knee articular cartilage integrity detected through OARSI 
score in WT (Sham and MNX) and Hfe-KO (Sham and MNX) mice. (n=10). Results described are a result of 
the summed OARSI score average between the three levels evaluated in the articular cartilage of each mice 
by two independent observers. The associated error is the confidence interval at 95%. Statistical analysis 
was done by Two-way ANOVA, followed by Tukey multiple comparison test with p<0.05 for each group 
analysed (WT sham, WT MNX, Hfe-KO Sham and Hfe-KO MNX) in tibia and femur. Comparisons between 
tibia and femur results were done by Paired T-test with p<0.05 for significance. a) statistical significance 
with p<0.05 between Sham and MNX groups within each genotype. b) Statistical significance between WT 
MNX and Hfe-KO MNX with p<0.05. * Statistical significance between tibia and femur with p<0.05. B- 
Detection of disintegrin and metallopeptidase with thrombospondin motifs (ADAMTS-5) and matrix 
metallopeptidase 3 (MMP-3) in articular cartilage.- Immunohistochemistry for knee articular cartilage in tibia 
of control (WT MNX) and Hfe-KO (Hfe-KO MNX) mice at 8 weeks after MNX surgery. ADAMTS5 and MMP3 
detection was done with DAB Kit SK4100 and correspond to brown staining. Counterstaining was done with 
1% methyl green, which stains hyaline cartilage tissues. The comparison between WT and Hfe-KO showed 
higher degree of ADAMTS5 and MMP3 detection in Hfe-KO mice relative to WT. 
338x190mm (96 x 96 DPI) 
Page 34 of 34BioFactors
